A Phase 4 interventional study of INC424 in Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF) and Post Essential Thrombocythaemia Myelofibrosis (PET-MF), sponsored by Novartis Pharmaceuticals. Completed at 10 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 24th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 4, and was the 12th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
24 studies in Primary Myelofibrosis by Novartis: 1 open now, 4 under way, 2 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2012, is one of 2 in phase 4, and was the 8th registered.
Novartis’s Primary Myelofibrosis studies by the year they started, since 2001.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Novartis’s 24 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of INC424 in patients with PMF, PPV MF, or PET-MF using a composite measure of either an objective endpoint (> 50% reduction in splenomegaly using palpitation at 48 weeks) and/or a subjective endpoint (>50% reduction in total symptom score at 48 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with PMF requiring therapy must be classified as high risk (3 prognostic factors) OR intermediate risk level 2 (2 prognostic factors, no more), OR intermediate risk level 1 (1 prognostic factor, no more) with an enlarged spleen. The prognostic factors, defined by the International Working Group are:
Exclusion criteria:
Patients with inadequate bone marrow reserve as demonstrated by:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
Drug: INC424
Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
Percentage of Participants With Treatment Success
Treatment success was defined as a 50% or greater reduction in palpable spleen length versus baseline at 48 weeks and/or a 50% or greater improvement in total symptom score (derived from the MF symptom assessment form (MFSAF) questionnaire) versus baseline at the week 48 time point. The MFSAF assesses the following symptoms (all scored from absent (0) to worst imaginable (10)): general fatigue, abdominal pain (and discomfort), inactivity (ability to move and walk around), cough, night sweats, itching (pruritus), bone pain (diffuse not joint pain or arthritis), fever, change in appetite/unintentional weight loss (or gain) in past 6 months, overall quality of life (QoL).
Time frame: 48 Weeks
Percentage of Participants With Best Overall Response
Response to treatment and disease progression was assessed by physical examination, specifically assessing changes in spleen size by palpation. Disease response and progression was evaluated using the International Working Group for myelofibrosis Research and Treatment Response Criteria.
Time frame: week 48
Change From Baseline in Myelofibrosis Symptoms Assessment Form (MF-SAF)
The MF-SAF consists of seven questions about key symptoms and impact of MF. Questions are scored on a scale of 0-10, with higher scores indicating more severe symptoms and greater inactivity. Questions 1-6, which together comprise a Total Symptom Score (TSS), investigate the following symptoms: night sweats, pruritus/itching, abdominal discomfort, pain under the ribs, early satiety and bone/muscle pain. Question 7 asks patients to report levels of inactivity. The TSS reflects the sum of the scores of these symptoms excluding inactivity, with the maximum possible score being 60 (most severe symptom experienced).
Time frame: Baseline, week 4, week 12, week 24, week 48
Change From Baseline in EQ5D Preference Index (5 Level EuroQol Questionnaire Determining Quality of Life) From Baseline
The EQ-5D is a standardized instrument used for measuring health outcomes in a wide range of health conditions and treatment. It consists of a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The EQ-VAS records the participant's self-rated health on a vertical, VAS where the endpoints are labeled 'best imaginable health state' and 'worst imaginable health state'. The EQ-5D health state was converted to a single summary index by applying a formula that attaches a weight to each of the levels in each dimension. The final EQ5D preference index scores range from 0 to 1 with higher scores indicating better health.
Time frame: Baseline, week 4, week 12, week 24, week 48
Number of Hospitalizations
Medical resource utilization (MRU) was assessed according to the number of hospitalizations.
Time frame: week 12, week 24, week 26, week 48
Duration of Hospitalizations
MRU was assessed according to the mean duration of hospitalization visits.
Time frame: week 48
Number of Accident & Emergency Visits From Baseline
MRU was assessed according to the number of accidents and emergency room visits.
Time frame: baseline to week 12, week 12 to week 24, week 24 to week 36, week 36 to week 48
Number of General Practitioner (GP), Specialists' and Urgent Care Visits
MRU was assessed according to the number of GP, specialists', and urgent care visits.
Time frame: baseline to week 12, week 12 to, week 24, week 24 to week 36, week 36 to week 48
Percentage of Participants With Transfusion Dependency Status
Transfusion dependency status from baseline through the end of study was assessed. New onset of transfusion dependency was defined as the use of 2 or more units of red blood cell products during the 8 weeks prior to a study visit. New onset of transfusion independency was defined as the use of 0 or 1 unit of red blood cell products during the 8 weeks prior to a study visit.
Time frame: baseline (BL), end of treatment (up to 28 days post last treatment) (EOT)
54 patients were screened. 48 patients were enrolled as planned.
| Milestone | INC424 |
|---|---|
| Started | 48 |
| Completed | 31 |
| Not completed | 17 |
| Withdrew: Adverse event | 7 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Death | 3 |
| Withdrew: Disease progression | 4 |
| Withdrew: Protocol violation | 1 |
Treatment success was defined as a 50% or greater reduction in palpable spleen length versus baseline at 48 weeks and/or a 50% or greater improvement in total symptom score (derived from the MF symptom assessment form (MFSAF) questionnaire) versus baseline at the week 48 time point. The MFSAF assesses the following symptoms (all scored from absent (0) to worst imaginable (10)): general fatigue, abdominal pain (and discomfort), inactivity (ability to move and walk around), cough, night sweats, itching (pruritus), bone pain (diffuse not joint pain or arthritis), fever, change in appetite/unintentional weight loss (or gain) in past 6 months, overall quality of life (QoL).
| Percentage of participants | INC424 |
|---|---|
| Percentage of Participants With Treatment Success | 50 |
Response to treatment and disease progression was assessed by physical examination, specifically assessing changes in spleen size by palpation. Disease response and progression was evaluated using the International Working Group for myelofibrosis Research and Treatment Response Criteria.
| Percentage of participants | INC424 |
|---|---|
| Clinical improvement | 6.3 |
| Complete response | 6.3 |
| Partial response | 39.6 |
| Stable disease | 47.9 |
The MF-SAF consists of seven questions about key symptoms and impact of MF. Questions are scored on a scale of 0-10, with higher scores indicating more severe symptoms and greater inactivity. Questions 1-6, which together comprise a Total Symptom Score (TSS), investigate the following symptoms: night sweats, pruritus/itching, abdominal discomfort, pain under the ribs, early satiety and bone/muscle pain. Question 7 asks patients to report levels of inactivity. The TSS reflects the sum of the scores of these symptoms excluding inactivity, with the maximum possible score being 60 (most severe symptom experienced).
| score on a scale | INC424 |
|---|---|
| Week 4 (n=37) | -8.78 ± 10.638 |
| Week 12 (n=35) | -8.46 ± 12.871 |
| Week 24 (n=30) | -9.13 ± 11.950 |
| Week 48 (n=18) | -7.83 ± 9.966 |
The EQ-5D is a standardized instrument used for measuring health outcomes in a wide range of health conditions and treatment. It consists of a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The EQ-VAS records the participant's self-rated health on a vertical, VAS where the endpoints are labeled 'best imaginable health state' and 'worst imaginable health state'. The EQ-5D health state was converted to a single summary index by applying a formula that attaches a weight to each of the levels in each dimension. The final EQ5D preference index scores range from 0 to 1 with higher scores indicating better health.
| unit on a scale | INC424 |
|---|---|
| week 4 (n=40) | 0.06 ± 0.173 |
| week 12 (n=38) | 0.05 ± 0.178 |
| week 24 (n=34) | 0.05 ± 0.231 |
| week 48 (n=29) | 0.03 ± 0.222 |
Medical resource utilization (MRU) was assessed according to the number of hospitalizations.
| number of hospitalizations | INC424 |
|---|---|
| week 12 (n=48) | 0.10 ± 0.371 |
| week 24 (n=40) | 0.03 ± 0.158 |
| week 36 (n=37) | 0.05 ± 0.229 |
| week 48 (n=35) | 0.09 ± 0.284 |
MRU was assessed according to the mean duration of hospitalization visits.
| days | INC424 |
|---|---|
| Duration of Hospitalizations | 9.00 ± 5.852 |
MRU was assessed according to the number of accidents and emergency room visits.
| Number of visits | INC424 |
|---|---|
| baseline to week 12 (n=48) | 0.00 ± 0.412 |
| week 12 to week 24 (n=39) | 0.00 ± 0.160 |
| week 24 to week 36 (n=33) | 0.00 ± 0.415 |
| week 36 to week 48 (n=33) | 0.00 ± 0.242 |
MRU was assessed according to the number of GP, specialists', and urgent care visits.
| number of visits | INC424 |
|---|---|
| GP visits, baseline to week 12 (n=45) | 0.0 (0.0 to 4.0) |
| GP visits, week 12 to week 24 (n=36) | 0.0 (0.0 to 1.0) |
| GP visits, week 24 to week 36 (n=33) | 0.0 (0.0 to 2.0) |
| GP visits, week 36 to week 48 (n=33) | 0.0 (0.0 to 3.0) |
| Specialists visits, baseline to week 12 (n=47) | 0.00 (0.0 to 8.0) |
| Specialists visits, week 12 to week 24 (n=36) | 0.00 (0.0 to 2.0) |
| Specialists visits, week 24 to week 36 (n=33) | 0.00 (0.0 to 4.0) |
| Specialists visits, week 36 to week 48 (n=33) | 0.00 (0.0 to 3.0) |
| Urgent care visits, baseline to week 12 (n=48) | 0.00 (0.0 to 1.0) |
| Urgent care visits, week 12 to week 24 (n=39) | 0.00 (0.0 to 0.0) |
| Urgent care visits, week 24 to week 36 (n=33) | 0.00 (0.0 to 1.0) |
| Urgent care visits, week 36 to week 48 (n=33) | 0.00 (0.0 to 1.0) |
Transfusion dependency status from baseline through the end of study was assessed. New onset of transfusion dependency was defined as the use of 2 or more units of red blood cell products during the 8 weeks prior to a study visit. New onset of transfusion independency was defined as the use of 0 or 1 unit of red blood cell products during the 8 weeks prior to a study visit.
| Percentage of participants | INC424 |
|---|---|
| From independency at BL to independency at EOT | 0.0 |
| From dependency at BL to independency at EOT | 2.1 |
| From missing at BL to independency at EOT | 0.0 |
| From independency at BL to dependency at EOT | 0.0 |
| From dependency at BL to dependency at EOT | 10.4 |
| From missing at BL to dependency at EOT | 35.4 |
| From independency at BL to missing at EOT | 0.0 |
| From dependency at BL to missing at EOT | 0.0 |
| From missing at BL to missing at EOT | 52.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| INC424 | — | 23/48 (47.9%) | 47/48 (97.9%) |
| Event | INC424 |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/48 |
| SplenomegalyBlood and lymphatic system disorders | 2/48 |
| Abdominal painGastrointestinal disorders | 2/48 |
| Staphylococcal sepsisInfections and infestations | 2/48 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/48 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/48 |
| Atrial fibrillationCardiac disorders | 1/48 |
| CataractEye disorders | 1/48 |
| Eyelid ptosisEye disorders | 1/48 |
| Event | INC424 |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 20/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 17/48 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 12/48 |
| Abdominal painGastrointestinal disorders | 11/48 |
| DiarrhoeaGastrointestinal disorders | 11/48 |
| FatigueGeneral disorders | 11/48 |
| ContusionInjury, poisoning and procedural complications | 11/48 |
| HeadacheNervous system disorders | 11/48 |
| LethargyNervous system disorders | 10/48 |
| DizzinessNervous system disorders | 9/48 |
All enrolled patients were included in the Full Analysis Set and the Safety Set.
| Age, Continuous(Years) | INC424 |
|---|---|
| Mean | 69.12 ± 10.419 |
| Sex: Female, Male(Participants) | INC424 |
|---|---|
| Female | 21 |
| Male | 27 |
The record gives a start of May 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib